ArticleInternational journal of nanomedicine2026
Anti-Trop2-Guided Liposomes Restore Methotrexate Sensitivity in Chemoresistant Gestational Trophoblastic Neoplasia.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Methotrexate (MTX) resistance limits its clinical efficacy in gestational trophoblastic neoplasia (GTN). To develop safer treatment strategies for patients of reproductive age, this study aims to investigate whether anti-trophoblast cell surface antigen 2 (Anti-Trop2) facilitates the tumor-targeted delivery of MTX-loaded liposomes, thereby enhancing drug sensitivity in chemoresistant GTN. Methods: Clinical samples were collected to detect trophoblast cell surface antigen 2 (Trop2) in MTX-resistant GTN. A methotrexate-loaded targeted liposome (A-Lipo@MTX) was designed and fully characterized. In vitro experiments were performed to evaluate the cellular uptake efficiency and cytotoxicity of the liposomes in MTX-resistant JEG3 cells (JEG3R), and to explore the underlying mechanism. The antitumor efficacy against drug-resistant tumors and initial biosafety of A-Lipo@MTX were further assessed in animal models. Results: Clinical specimens revealed that Trop2 was significantly upregulated in chemoresistant GTN tissues. Trop2 could serve as a potential therapeutic target for drug-resistant tumors. The designed A-Lipo@MTX exhibited a uniform nanoscale size (~210 nm), high encapsulation efficiency (~85%), and favorable stability. In vitro, Anti-Trop2 functionalization significantly increased liposomal endocytosis within MTX-resistant GTN cells; the resulting intracellular MTX accumulation inhibited PI3K-AKT-mTOR signaling and triggered tumor cell apoptosis. In vivo imaging results confirmed its increased tumor accumulation, which translated into superior antitumor efficacy. Importantly, A-Lipo@MTX improved biosafety during medication, as indicated by stable body weight, normal serum biochemical parameters, and minimal organ damage. Conclusion: This study identifies Trop2 as an effective target to promote liposome specific uptake, elevates intratumoral MTX accumulation at tumor sites, and suppress the activation of drug-resistant signaling pathways. This strategy provides a clinically relevant and safer approach for overcoming chemoresistance in GTN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.